New bladder cancer drug enters first human tests

NCT ID NCT07483970

Recruiting now Disease control Sponsor: Jecho Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This early-stage trial tests a new drug called JL19001, given alone or with standard BCG therapy, in 18 people with high-risk non-muscle invasive bladder cancer. The main goals are to check safety, find the right dose, and see how the body handles the drug. It's a first step to see if this approach is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JL19001 injection
What this could lead to: If successful, this could point toward a new treatment option for high-risk bladder cancer that hasn't spread into the muscle.
What could go wrong: This is a very early Phase 1 trial with only 18 people, so it's mainly checking safety and dosing. It's too soon to know if it works, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

superficial urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Locations

West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.